-
Abstract Number: 509
Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program
-
Abstract Number: 510
Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels
-
Abstract Number: 511
A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials
-
Abstract Number: 512
Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY
-
Abstract Number: 513
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks
-
Abstract Number: 514
A Pooled Analysis of 1-year Clinical Outcomes Among 6-month Responders and Non-responders from Three Randomized Controlled Studies of TNF Inhibitor Biosimilars in Patients with Rheumatoid Arthritis
-
Abstract Number: 515
Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib
-
Abstract Number: 516
Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib
-
Abstract Number: 517
A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
-
Abstract Number: 518
Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
-
Abstract Number: 519
Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components
-
Abstract Number: 520
Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA
-
Abstract Number: 521
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
-
Abstract Number: 522
Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis
-
Abstract Number: 523
The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 198
- Next Page »